- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02566707
Pharmacokinetics of Atazanavir /Dolutegravir/Lamivudine Regimen as Maintenance Regimen (PRADAII)
December 4, 2020 updated by: Radboud University Medical Center
Pharmacokinetics, Safety and Efficacy of Atazanavir /Dolutegravir/Lamivudine Regimen as Maintenance Regimen in Patients With Intolerance and/or Resistance to NRTIs, NNRTIs and RTV: A Pilot Study
During the past years the treatment of HIV-1 infection has transformed towards chronic treatment.
Patients are being treated with antiretroviral drugs for many years and become older.
The risk of developing side-effects due to long term antiretroviral therapy is therefore more and more likely.
New alternative once-daily maintenance regimes are needed for those who are extensively pre-treated and experience side-effects or toxicity on standard treatment combinations.
A possible once-daily, fully active maintenance regimen is the combination of atazanavir (unboosted), dolutegravir and lamivudine (PRADAII regimen).
This combination is expected to be a safe, once-daily maintenance regimen with a favorable side-effect profile.
The combination suits patients with intolerance and/or resistance to NRTIs, NNRTIs and ritonavir, who have a suppressed viral load.
However, for this new combination the pharmacokinetic profile is unknown and there are no data on short-term and long-term safety and efficacy.
This study wille therefore asses the pharmacokinetics, safety and efficacy in a small number of HIV-1 infected patients.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
9
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Bonn, Germany
- University of Bonn
-
-
-
-
-
Arnhem, Netherlands
- Rijstate
-
Nijmegen, Netherlands
- Radboud University Nijmegen Medical Centre
-
Tilburg, Netherlands
- St. Elisabeth
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- HIV-infected as documented by positive HIV antibody test and confirmed by Western Blot.
- Subject is in need for a switch in maintenance regimen due to adverse effects, toxicities, simplification and/or resistance.
- Subject is at least 18 years of age at the day of screening.
- Subject is able and willing to sign the Informed Consent Form prior to screening evaluations.
- HIV-1 RNA < 40 copies/mL for at least 6 months on antiretroviral therapy prior to inclusion.
- Subject has no documented resistance mutations to PIs, INSTIs or lamivudine.
Exclusion Criteria:
- Documented history of sensitivity/idiosyncrasy to medicinal products or excipients.
- Relevant history or current condition that might interfere with drug absorption, distribution, metabolism or excretion.
- Inability to understand the nature and extent of the trial and the procedures required.
- Pregnant female (as confirmed by an HCG test performed less than 3 weeks before the first dose) or breast-feeding female.
- Abnormal serum transaminases determined as levels being > 5 times upper limit of normal.
- Renal failure determined as an estimated Glomerular Filtration Rate (eGFR) < 50 ml/min (MDRD-based).
- Concomitant use of medications that interfere with atazanavir, dolutegravir or lamivudine pharmacokinetics: oxcarbazepine, phenytoin, phenobarbital, carbamazepine, St. John's wort, rifampicin, clarithromycin, H2 receptor antagonists, proton pump inhibitors, irinotecan, midazolam, triazolam, buprenorphine, aprepitant, modafinil, imatinib, co-trimoxazole, other antiretroviral drugs.
- Concomitant use of medications that are contraindicated for use with atazanavir, dolutegravir or lamivudine: alfuzosin, dofetilide, pimozide, quetiapine, quinidine, bepridil, simvastatin, atorvastatin, lovastatin, sildenafil (as for use in pulmonary arterial hypertension), cladribine.
- Active hepatobiliary or hepatic disease (including chronic hepatitis B or C infection).
- Alcohol abuse.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: PRADAII regimen
Use of PRADAII regimen during 12 weeks.
This regimen consists of atazanavir 400 mg QD, dolutegravir 50 mg QD, lamivudine 300 mg QD.
|
HIV therapy will be adapted: atazanavir 400mg QD
Other Names:
HIV therapy will be adapted: dolutegravir 50mg QD
Other Names:
HIV therapy will be adapted: lamivudine 300mg QD
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Area under the plasma concentration versus time curve (AUC) of atazanavir, dolutegravir and lamivudine
Time Frame: week 2
|
Pharmacokinetic parameters of atazanavir, dolutegravir and lamivudine
|
week 2
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
efficacy (viral load)
Time Frame: week 2, 6 and 12
|
efficacy (viral load) of the combination of atazanavir, dolutegravir and lamivudine
|
week 2, 6 and 12
|
number of adverse events
Time Frame: week 2, 6 and 12
|
number of adverse events of the combination of atazanavir, dolutegravir and lamivudine
|
week 2, 6 and 12
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2015
Primary Completion (Actual)
December 1, 2016
Study Completion (Actual)
December 1, 2016
Study Registration Dates
First Submitted
September 2, 2015
First Submitted That Met QC Criteria
October 1, 2015
First Posted (Estimate)
October 2, 2015
Study Record Updates
Last Update Posted (Actual)
December 7, 2020
Last Update Submitted That Met QC Criteria
December 4, 2020
Last Verified
December 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Reverse Transcriptase Inhibitors
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Anti-HIV Agents
- Anti-Retroviral Agents
- Protease Inhibitors
- HIV Integrase Inhibitors
- Integrase Inhibitors
- HIV Protease Inhibitors
- Viral Protease Inhibitors
- Lamivudine
- Atazanavir Sulfate
- Dolutegravir
Other Study ID Numbers
- UMCN-AKF 14.08
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV-1 Infection
-
Sociedad Andaluza de Enfermedades InfecciosasConsejeria de Salud. Junta de Andalucia. SpainCompletedHIV Infection | HIV-1 InfectionSpain
-
Helios SaludViiV HealthcareUnknownHiv | HIV-1-infectionArgentina
-
Frontier Biotechnologies Inc.RecruitingHIV-1-infectionUnited States
-
University of ZurichActive, not recruitingHIV-1-infectionSwitzerland
-
MacroGenicsNational Institute of Allergy and Infectious Diseases (NIAID)CompletedHIV-1-infectionUnited States
-
Fundación FLS de Lucha Contra el Sida, las Enfermedades...Aelix TherapeuticsCompleted
-
University of North Carolina, Chapel HillNational Institute of Allergy and Infectious Diseases (NIAID)CompletedHIV-1 InfectionUnited States
-
Taipei Veterans General Hospital, TaiwanCompleted
-
Shanghai Public Health Clinical CenterUnknown
-
Fundación FLS de Lucha Contra el Sida, las Enfermedades...Completed
Clinical Trials on Atazanavir
-
Bristol-Myers SquibbCompleted
-
Asan Medical CenterBristol-Myers SquibbUnknown
-
Radboud University Medical CenterDutch Diabetes Research FoundationCompletedEffects of Atazanavir Treatment on Type 2 Diabetes Mellitus Related Endothelial Dysfunction (DM2ATV)Type 2 Diabetes Mellitus Related Endothelial DysfunctionNetherlands
-
Bristol-Myers SquibbCompleted
-
Bristol-Myers SquibbCompleted
-
Bristol-Myers SquibbMerck Sharp & Dohme LLCCompleted
-
Bristol-Myers SquibbCompleted
-
Giovanni Di PerriUniversity of Turin, Italy; University of MilanTerminatedHIV Infection | OsteopeniaItaly
-
Bristol-Myers SquibbCompletedHuman Immunodeficiency Virus Type 1 (HIV-1)United States
-
University of British ColumbiaCompleted